Age-Related Macular Degeneration: PEDigree clinical trial of iSONEP
Nexus Trial to Study Effects of iSONEP in Wet AMD Patients Without RPE Detachment
Lpath Initiates Dosing of iSONEP in Second of Two Proof-of-Concept Trials
iSONEP ™ and ASONEP(TM) are different formulations of a first-in-class therapeutic antibody developed by Lpath's ImmuneY2(TM) drug-discovery engine. Antibodies developed via this discovery engine are designed to target bioactive signaling lipids, such as S1P, that are involved in the proliferation and spread of cancer, age-related macular degeneration (AMD), inflammatory and auto-immune disorders, and many other diseases.
Read Nexus Trial to Study Effects of iSONEP in Wet AMD Patients Without RPE Detachment
PEDigree Trial to Study Effects of iSONEP in Patients With RPE Detachment
Lpath Initiates Dosing of iSONEP in First of Two Proof-of-Concept Trials
In this human proof-of-concept trial, Lpath plans to dose 32 subjects -- 16 at a lower dose and 16 at a higher dose -- that have PED secondary to wet age-related macular degeneration (wet AMD) or polypoidal choroidal vasculopathy (PCV).
Read PEDigree Trial to Study Effects of iSONEP in Patients With RPE Detachment
Lpath intiates patient enrollment in PEDigree clinical trial
Lpath intends to start another iSONEP trial in June of this year, a Phase 2 human-proof-of-concept trial to study the efficacy and safety of iSONEP in wet AMD patients that do not have PED.
Read Lpath intiates patient enrollment in PEDigree clinical trial
Lpath Initiates Enrollment of iSONEP Phase 1b/2a Proof-of-Concept Trial
In this Phase 1b/2a trial, Lpath plans to dose 32 subjects that have retinal pigment epithelium detachment (PED) that is secondary to wet age-related macular degeneration (wet AMD) or polypoidal choroidal vasculopathy (PCV).
Read Lpath Initiates Enrollment of iSONEP Phase 1b/2a Proof-of-Concept Trial
Lpath Granted Another Key U.S. Patent Related to iSONEP and ASONEP Drug Programs
Lpath will soon initiate two iSONEP Phase II trials: The PEDigree Study will evaluate the safety and efficacy of iSONEP in patients with RPE Detachment (PED), for which there is no approved drug, and the Nexus Study will evaluate the safety and efficacy in wet-AMD patients without PED.
Read Lpath Granted Another Key U.S. Patent Related to iSONEP and ASONEP Drug Programs
Multiple Phase 2 Trials and Pfizer Partnership Provide Path to ProfitsPEDigree Phase Ib/2a preliminary data Q4 2011 and additional Phase 2 trial data 2012
ISONEP is currently beginning Phase 1b/2a trials for the treatment of wet-form AMD. With wet macular degeneration, new blood vessels grow beneath the retina and leak blood and fluid.
Read Multiple Phase 2 Trials and Pfizer Partnership Provide Path to Profits
Lpath Grants Pfizer Exclusive Option for Worldwide License for iSONEP
Lpath Grants Pfizer Exclusive Option for Worldwide License for iSONEP
iSONEP is scheduled to begin a Phase 1b clinical trial in wet AMD patients with Pigment Epithelial Detachment (PED), a complication of wet AMD, in the first quarter of 2011 and a Phase 2a clinical trial in wet AMD patients in the second quarter of 2011.
Positive phase-1 clinical trial results for ISONEP in AMD
Lpath, Inc. reported positive results of its single-dose Phase 1 clinical trial of iSONEP, an anti-sphingosine-1-phosphate monoclonal antibody, in neovascular age-related macular degeneration (AMD) patients.
Read Positive phase-1 clinical trial results for ISONEP in AMD
iSONEP Targets SIP in AMD
Will another cancer drug prove to be effective in treating AMD?
Since Philip J. Rosenfeld, MD, PhD, of Bascom Palmer Eye Center in Miami, began using bevacizumab in patients with AMD - if not before then - the treatment of neovascular AMD and resolution of choroidal neovascularization has been linked to the development of treatments designed to prevent metastasis of cancer.
Read iSONEP Targets SIP in AMD